HALT Study Page | TriviumVet

PRR-REGISTER INTEREST NOW

The HALT HCM Study is a blinded, randomized, placebo-controlled trial of TRIV202 in the management of ventricular hypertrophy associated with feline subclinical hypertrophic cardiomyopathy (HCM). The objective of the study is to determine the effectiveness and safety of 12 months’ dosing of once-weekly TRIV202 in feline subclinical HCM. The study will be conducted at 15-20 clinical sites in the United States, United Kingdom, and Europe that are experienced in treating cats with HCM. It will aim to enroll 300 cats.

Vet taking information with pet owner and cat

Take Part In Our Clinical Trials

TriviumVet is dedicated to raising the standard of treatment for some of the most serious medical conditions in pets. This requires quality clinical research, and for that we need your help. There are several different ways you can be part of our research driving therapeutic advances to enhance the lives of pets and the people who love them.

Having a pet with a serious health problem is frightening. Participating in a trial that is investigating a promising new therapy can not only provide hope for your pet, but it may also allow you and your pet to be part of research that brings hope to many more pets and owners.

View Our Clinical Trials

News

28th July

Feline HCM product prevented progression of hypertrophy - Results of the RapaCat Study published in JAVMA

TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our novel, proprietary veterinary mTOR inhibitor TRIV202 to target early Hypertrophic Cardiomyopathy (HCM) and was tested in stage B1...